Cargando…

Detection of Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers

IMPORTANCE: Novel plasma biomarkers, especially phosphorylated tau (p-tau), can detect brain tau aggregates in Alzheimer disease. OBJECTIVE: To determine which plasma biomarker combinations can accurately detect tau pathological brain changes in Down syndrome (DS). DESIGN, SETTING, AND PARTICIPANTS:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Janelidze, Shorena, Christian, Bradley T., Price, Julie, Laymon, Charles, Schupf, Nicole, Klunk, William E., Lott, Ira, Silverman, Wayne, Rosas, H. Diana, Zaman, Shahid, Mapstone, Mark, Lai, Florence, Ances, Beau M., Handen, Benjamin L., Hansson, Oskar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2022
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9257682/ https://www.ncbi.nlm.nih.gov/pubmed/35789365 http://dx.doi.org/10.1001/jamaneurol.2022.1740

Ejemplares similares

Role of tau deposition in early cognitive decline in Down syndrome
por: Hartley, Sigan L., et al.
Publicado: (2022)

The Alzheimer's Biomarker Consortium‐Down Syndrome: Rationale and methodology
por: Handen, Benjamin L., et al.
Publicado: (2020)

Metabolic correlates of prevalent mild cognitive impairment and Alzheimer's disease in adults with Down syndrome
por: Mapstone, Mark, et al.
Publicado: (2020)

Proteomic profiles for Alzheimer's disease and mild cognitive impairment among adults with Down syndrome spanning serum and plasma: An Alzheimer's Biomarker Consortium–Down Syndrome (ABC–DS) study
por: Petersen, Melissa E., et al.
Publicado: (2020)

Cerebrospinal fluid biomarkers of Alzheimer's disease in a cohort of adults with Down syndrome
por: Henson, Rachel L., et al.
Publicado: (2020)

Neurofibrillary tau depositions emerge with subthreshold cerebral beta-amyloidosis in down syndrome
por: Zammit, Matthew D., et al.
Publicado: (2021)

Timing of Alzheimer’s Disease by Intellectual Disability Level in Down Syndrome
por: Hartley, Sigan L., et al.
Publicado: (2023)

Impact of the COVID-19 pandemic on daily life, mood, and behavior of adults with Down syndrome
por: Hartley, Sigan L., et al.
Publicado: (2022)

Amyloid- β and tau deposition influences cognitive and functional decline in Down syndrome
por: Grigorova, Monika, et al.
Publicado: (2022)

Relationship of amyloid beta and neurofibrillary tau deposition in Neurodegeneration in Aging Down Syndrome (NiAD) study at baseline
por: Tudorascu, DL, et al.
Publicado: (2020)

White matter microstructure associations with episodic memory in adults with Down syndrome: a tract-based spatial statistics study
por: Bazydlo, Austin, et al.
Publicado: (2021)

PET measurement of longitudinal amyloid load identifies the earliest stages of amyloid-beta accumulation during Alzheimer’s disease progression in Down syndrome
por: Zammit, Matthew D., et al.
Publicado: (2021)

Mitigating the Associations of Kidney Dysfunction With Blood Biomarkers of Alzheimer Disease by Using Phosphorylated Tau to Total Tau Ratios
por: Janelidze, Shorena, et al.
Publicado: (2023)

A modified Cued Recall Test for detecting prodromal AD in adults with Down syndrome
por: Krinsky‐McHale, Sharon J., et al.
Publicado: (2022)

White matter microstructure associations to amyloid burden in adults with Down syndrome
por: Bazydlo, Austin M., et al.
Publicado: (2021)

Cognitive indicators of transition to preclinical and prodromal stages of Alzheimer's disease in Down syndrome
por: Hartley, Sigan L., et al.
Publicado: (2020)

Language skills as a predictor of cognitive decline in adults with Down syndrome
por: Pulsifer, Margaret B., et al.
Publicado: (2020)

Acute Regression in Down Syndrome
por: Handen, Benjamin, et al.
Publicado: (2021)

β-Amyloid–Dependent and –Independent Genetic Pathways Regulating CSF Tau Biomarkers in Alzheimer Disease
por: Kumar, Atul, et al.
Publicado: (2022)

Assessing general cognitive and adaptive abilities in adults with Down syndrome: a systematic review
por: Hamburg, Sarah, et al.
Publicado: (2019)

Cellular localization of p-tau217 in brain and its association with p-tau217 plasma levels
por: Wennström, Malin, et al.
Publicado: (2022)

Plasma Phospho‐Tau Identifies Alzheimer's Co‐Pathology in Patients with Lewy Body Disease
por: Hall, Sara, et al.
Publicado: (2020)

Joint‐label fusion brain atlases for dementia research in Down syndrome
por: Queder, Nazek, et al.
Publicado: (2022)

Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays
por: Leuzy, Antoine, et al.
Publicado: (2021)

Cortical atrophy and amyloid and tau deposition in Down syndrome: A longitudinal study
por: Padilla, Concepcion, et al.
Publicado: (2022)

Aging and Down Syndrome
por: Head, Elizabeth, et al.
Publicado: (2012)

Plasma p-tau181 and p-tau217 in discriminating PART, AD and other key neuropathologies in older adults
por: Yu, Lei, et al.
Publicado: (2023)

Altered connectivity of the default mode network in cognitively stable adults with Down syndrome: “Accelerated aging” or a prelude to Alzheimer's disease?
por: Rosas, H. Diana, et al.
Publicado: (2021)

Cognitive Function during the Prodromal Stage of Alzheimer’s Disease in Down Syndrome: Comparing Models
por: Hom, Christy L., et al.
Publicado: (2021)

Pathways linking pulse pressure to dementia in adults with Down syndrome
por: Rizvi, Batool, et al.
Publicado: (2023)

Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease
por: Janelidze, Shorena, et al.
Publicado: (2020)

Amyloid accumulation in Down syndrome measured with amyloid load
por: Zammit, Matthew D., et al.
Publicado: (2020)

Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
por: Mattsson‐Carlgren, Niklas, et al.
Publicado: (2021)

Towards a unified protocol for handling of CSF before β-amyloid measurements
por: Janelidze, Shorena, et al.
Publicado: (2019)

Patterns of glucose hypometabolism in Down syndrome resemble sporadic Alzheimer's disease except for the putamen
por: Zammit, Matthew D., et al.
Publicado: (2021)

Physical activity, memory function, and hippocampal volume in adults with Down syndrome
por: Peven, Jamie C., et al.
Publicado: (2022)

Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects
por: Pereira, Joana B, et al.
Publicado: (2021)

Correction: Hom et al. Cognitive Function during the Prodromal Stage of Alzheimer’s Disease in Down Syndrome: Comparing Models. Brain Sci. 2021, 11, 1220
por: Hom, Christy L., et al.
Publicado: (2022)

Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals
por: Groot, Colin, et al.
Publicado: (2022)

Down syndrome: Distribution of brain amyloid in mild cognitive impairment
por: Keator, David B., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_a3cbkvdfgjeeejverr6e91r4s9